相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Novel Pulmonary Delivery of Antiviral Drugs for Treating COVID-19 in Patients with Parkinson's Disease
Nazrul Islam et al.
CURRENT DRUG DELIVERY (2022)
Diagnosis, management, and outcomes of venous thromboembolism in COVID-19 positive patients: a role for direct anticoagulants?
Charalampos Kartsios et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)
Direct oral anticoagulant use and risk of severe COVID-19
B. Flam et al.
JOURNAL OF INTERNAL MEDICINE (2021)
Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic
Rachna Patel et al.
THROMBOSIS RESEARCH (2021)
Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study
Christopher T. Rentsch et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death
Florian Posch et al.
TRANSLATIONAL RESEARCH (2020)
Fibrin clot formation under diverse clotting conditions: Comparing turbidimetry and thromboelastography
Ziqian Zeng et al.
THROMBOSIS RESEARCH (2020)
COVID19 coagulopathy in Caucasian patients
Helen Fogarty et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy
Ning Tang et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Heparin as a therapy for COVID-19: current evidence and future possibilities
Joseph A. Hippensteel et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2020)
Development and characterization of meropenem dry powder inhaler formulation for pulmonary drug delivery
Saiqa Muneer et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2020)
Cerebral venous thrombosis in COVID-19-associated coagulopathy: A case report
Yohsuke Sugiyama et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2020)
Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia
Luca Costanzo et al.
JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS (2020)
Excipient Interactions in Glucagon Dry Powder Inhaler Formulation for Pulmonary Delivery
Md Abdur Rashid et al.
PHARMACEUTICS (2019)
Lytic Susceptibility, Structure, and Mechanical Properties of Fibrin in Systemic Lupus Erythematosus
Rustem Litvinov et al.
FRONTIERS IN IMMUNOLOGY (2019)
An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: communication from the SSC of the ISTH
M. Pieters et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Abnormal plasma clot formation and fibrinolysis reveal bleeding tendency in patients with partial factor XI deficiency
Gillian N. Gidley et al.
BLOOD ADVANCES (2018)
Alteration of clot architecture using bone substitute biomaterials (beta-tricalcium phosphate) significantly delays the early bone healing process
Xin Wang et al.
JOURNAL OF MATERIALS CHEMISTRY B (2018)
Nicotine hydrogen tartrate loaded chitosan nanoparticles: Formulation, characterization and in vitro delivery from dry powder inhaler formulation
Hui Wang et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2017)
PLGA Ethionamide Nanoparticles for Pulmonary Delivery: Development and in vivo evaluation of dry powder inhaler
Sujit Kumar Debnath et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2017)
Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
Dolly A. Parasrampuria et al.
CLINICAL PHARMACOKINETICS (2016)
Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis
Travis J. Gould et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
A synthetic fibrin cross-linking polymer for modulating clot properties and inducing hemostasis
Leslie W. Chan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency
M. Zucker et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects
Nobuko Matsushima et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2013)
Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines
Clive Kearon et al.
CHEST (2012)
An investigation into the dispersion mechanisms of ternary dry powder inhaler formulations by the quantification of interparticulate forces
Matthew D. Jones et al.
PHARMACEUTICAL RESEARCH (2008)
Quantification of phases with partial or no known crystal structures
Nicola V. Y. Scarlett et al.
POWDER DIFFRACTION (2006)
Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures
N Islam et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Lactose surface modification by decantation: Are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures?
N Islam et al.
PHARMACEUTICAL RESEARCH (2004)
The influence of carrier and drug morphology on drug delivery from dry powder formulations
H Larhrib et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2003)
Analyzing fibrin clot microplate reader
AS Wolberg et al.
BLOOD COAGULATION & FIBRINOLYSIS (2002)
分享论文
